2024
Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic
Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Obstetrical & Gynecological Survey 2024, 79: 643-644. DOI: 10.1097/01.ogx.0001095056.57063.30.Peer-Reviewed Original ResearchThrombotic thrombocytopenic purpuraFamily planning clinicsReproductive-age womenHerbal supplementsOral contraceptivesThrombocytopenic purpuraAdverse eventsPlanning clinicsDrug interactionsSupplement useCardiac arrhythmiasHerbal supplement useDepression medicationPrescription medicationsDrugGastrointestinal illnessMedicationRisk associated with interactionsSupplementationPurpuraContraceptionArrhythmiasThe influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users
Lazorwitz A, Sheeder J, Teal S. The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users. Contraception 2024, 140: 110539. PMID: 39002624, PMCID: PMC11588555, DOI: 10.1016/j.contraception.2024.110539.Peer-Reviewed Original ResearchContraceptive implant usersSerum etonogestrel concentrationsEtonogestrel concentrationsImplant usersEtonogestrel implant usersSteady-state pharmacokineticsLifestyle factorsIncreased caloric intakeInfluence of lifestyle factorsCaloric intakeSubstance useCross-sectional analysisEtonogestrelCurrent dietInconsistent associationsExercise habitsAssociationDietPharmacokineticsExerciseSerumSurvey responsesIntakeA retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals
Kendall P, Bresnitz W, Huang J, Sheeder J, Lazorwitz A. A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals. Contraception 2024, 137: 110486. PMID: 38754757, DOI: 10.1016/j.contraception.2024.110486.Peer-Reviewed Original ResearchContraceptive implant removalLower body mass indexBody mass indexImplant removalSuperficial removalWeight gainAssociated with younger ageRetrospective cohort studyMann-Whitney U testMultivariate logistic regressionAssociated with increased oddsFactors associated with increased likelihoodHealth record reviewContraceptive implantsImplant exchangeFischer's exactElectronic health record reviewImplant useComparing patientsRetrospective analysisMass indexCohort studyPatient characteristicsRemoval groupInserting contraceptive implantsPilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2024, 135: 110442. PMID: 38552822, DOI: 10.1016/j.contraception.2024.110442.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsMedian body mass indexMedian pain scoreBody mass indexTime pointsBleeding side effectsEtonogestrel implantImplant placementReproductive-age femalesENG implantSite painPain scoresMedian ageInsertion siteEtonogestrelMass indexPilot studyPatient populationInferior edgeSide effectsPharmacokineticsImplantationWeeksSerumSubstance Use and Anxiety About Pain Among Patients Seeking Abortion Services
Masten M, Sheeder J, Lazorwitz A. Substance Use and Anxiety About Pain Among Patients Seeking Abortion Services. Cureus 2024, 16: e57034. PMID: 38681459, PMCID: PMC11047799, DOI: 10.7759/cureus.57034.Peer-Reviewed Original ResearchNon-opioid usersPain-related anxietyAnonymous survey of patientsAnxiety scoresOpioid useSurvey of patientsCannabidiol useCannabidiol usersSubstance usersOpioid usersCross-sectional anonymous surveyPainMedian anxiety scorePatientsOpioidAbortionCannabidiolNon-usersSubstance useMarijuanaScoresAnxietyUseLetter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’
Kendall P, Lazorwitz A. Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’. Epidemiology And Psychiatric Sciences 2024, 33: e4. PMID: 38299323, PMCID: PMC10894698, DOI: 10.1017/s2045796024000039.Peer-Reviewed Original Research
2023
Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic
Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 323-329. PMID: 38061680, DOI: 10.1016/j.jpag.2023.11.012.Peer-Reviewed Original ResearchSupplement-drug interactionsYoung adult womenSupplement useHerbal medicineAdult womenGeneral health care providersCommon herbal supplementsCytochrome P450 enzyme inhibitionHormonal contraceptive therapyHerbal medicine useBaseline demographic characteristicsHerbal supplement useTitle X clinicsFamily Planning ClinicCurrent contraceptive methodHealth care providersCross-sectional surveyContraceptive therapyMenstrual irregularitiesCaffeine clearanceMedian ageMedicine usePlanning ClinicInteraction checkerGeneral healthFeasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution
Drake E, Larrea N, Wolverton E, Tibbits B, Lazorwitz A, Schultz C. Feasibility and Utility of Posttraumatic Stress Disorder Screening Among Postpartum Patients at an Urban Safety-Net Institution. Obstetrics And Gynecology 2023, 142: 1455-1458. PMID: 37884025, DOI: 10.1097/aog.0000000000005422.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderSafety-net institutionsPostpartum patientsStress disorderMonths of deliveryDepression screening resultsScreening resultsPositive scoreMost patientsPrimary outcomeRoutine careIdentified patientsPrimary careObstetric practitionersPatientsBehavioral healthCareDisordersScoresPeripartumPrevalenceMonthsAn exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users
Diamond B, Sheeder J, Lazorwitz A. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users. Contraception 2023, 129: 110298. PMID: 37802462, PMCID: PMC10842501, DOI: 10.1016/j.contraception.2023.110298.Peer-Reviewed Original ResearchConceptsMood-related side effectsContraceptive implant usersENG implant usersInter-individual variabilitySide effectsImplant usersEtonogestrel contraceptive implant usersMood changesWide inter-individual variabilitySerum etonogestrel concentrationsPHQ-9 scoresSerum drug levelsLiquid chromatography-mass spectrometry assaySubset of participantsEtonogestrel concentrationsPrimary outcomePharmacokinetic variabilityMood concernsBaseline questionnairePHQ-9Blood drawDrug levelsMood symptomsImplant usePossible associationValidation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel
Lazorwitz A, Sheeder J. Validation of 24-hour trough concentration as a proxy for intensive pharmacokinetic measurements for a combined oral contraceptive pill containing desogestrel. Contraception 2023, 126: 110093. PMID: 37331464, PMCID: PMC10528283, DOI: 10.1016/j.contraception.2023.110093.Peer-Reviewed Original ResearchThe effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study
Lazorwitz A, Sheeder J, Teal S. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study. Contraception 2023, 123: 110035. PMID: 36997081, PMCID: PMC10461170, DOI: 10.1016/j.contraception.2023.110035.Peer-Reviewed Original ResearchConceptsContraceptive implant usersSerum etonogestrel concentrationsStrong CYP3A inducersENG implant usersEtonogestrel concentrationsMedian ageImplant usersCYP3A inducersP4 concentrationsMedian body mass indexSerum E2 concentrationsBody mass indexSignificant decreaseParticipants' median ageSuppression of ovulationSerum P4 concentrationsEffect of rifampinDrug-drug interactionsLiquid chromatography-mass spectrometry assayOnly short exposuresWilcoxon signed-rank testBaseline E2Rifampin 600Rifampin exposureRifampin therapy
2022
Herbal supplement use among reproductive-aged women in an academic infertility practice
Friedman J, Sheeder J, Lazorwitz A, Polotsky A. Herbal supplement use among reproductive-aged women in an academic infertility practice. F&S Reports 2022, 4: 104-111. PMID: 36959959, PMCID: PMC10028423, DOI: 10.1016/j.xfre.2022.12.001.Peer-Reviewed Original ResearchAcademic infertility practiceSupplement-drug interactionsSupplement useHerbal medicineInfertility practiceInteraction checkerInfertility treatmentInfertility therapyHerbal supplementsGeneral health care providersDirect medical supervisionReproductive-aged patientsHerbal supplement useReproductive-aged womenThird of womenHealth care providersCross-sectional survey studyBaseline demographicsPatient demographicsMedian ageEarly pregnancyMedication interactionsHerbal medicationsSupplement interactionsGeneral healthP077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant
Clure C, Sheeder J, Lazorwitz A. P077Pilot study on a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant. Contraception 2022, 116: 91. DOI: 10.1016/j.contraception.2022.09.101.Peer-Reviewed Original ResearchEtonogestrel contraceptive implantContraceptive implantsENG implantENG levelsSide effectsMedian pain scoreTime pointsReproductive-aged womenScapular insertionPain scoresSite painMedian ageMedian BMIImplant useInferior edgeInsertion siteWeek twoYears of useFirst weekPilot studyImplant usersPharmacokineticsImplantsFirst yearWeeksP079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer
Lazorwitz A, Teal S, Sheeder J. P079Etonogestrel contraceptive implant users can experience breakthrough ovulation with only two weeks of exposure to a strong cyp3a inducer. Contraception 2022, 116: 92. DOI: 10.1016/j.contraception.2022.09.103.Peer-Reviewed Original ResearchStrong CYP3A inducersBreakthrough ovulationCYP3A inducersE2 concentrationsP4 concentrationsMedian ageOvulation suppressionImplant usersPg/Baseline serum concentrationsContraceptive implant usersEtonogestrel implant usersSerum E2 concentrationsParticipants' median ageSerum P4 concentrationsENG implant usersDrug-drug interactionsRifampin exposureMedian durationENG implantMedian BMIEndogenous estradiolSerum concentrationsSurrogate biomarkerWeeks of exposureShort-notice cancellations of laparoscopic permanent contraception
Masten M, Larrea N, Schultz C, Lazorwitz A. Short-notice cancellations of laparoscopic permanent contraception. Contraception 2022, 114: 49-53. PMID: 35545130, DOI: 10.1016/j.contraception.2022.04.013.Peer-Reviewed Original ResearchConceptsAcademic county hospitalSurgery cancellation ratesHigher cancellation rateCancellation ratePermanent contraceptionCounty HospitalContraceptive methodsAcademic tertiary care hospitalRetrospective cohort studyRetrospective chart reviewTertiary care hospitalPreferred contraceptive methodHealth care systemElectronic health recordsMost cancellationsChart reviewCohort studyCare hospitalSubsequent pregnancySurgery dateEffective contraceptionTubal sterilizationCommon reasonPatientsSurgeryHerbal Supplement Use Among Adolescent Women in a Family Planning Clinic
Friedman J, Sheeder J, Lazorwitz A. Herbal Supplement Use Among Adolescent Women in a Family Planning Clinic. Journal Of Pediatric And Adolescent Gynecology 2022, 35: 238. DOI: 10.1016/j.jpag.2022.01.120.Peer-Reviewed Original ResearchEffect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users
Lazorwitz A, Pena M, Sheeder J, Teal S. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users. Obstetrics And Gynecology 2022, 139: 579-587. PMID: 35594123, PMCID: PMC9140306, DOI: 10.1097/aog.0000000000004697.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsBody mass indexPg/Median ageImplant usersEnzyme-inducing antiepileptic drugsMedian body mass indexEffects of topiramateMean percent changeParticipants' median ageOvulatory suppressionTopiramate therapyMedian durationTopiramate useEtonogestrel implantsPharmacokinetic interactionsHealthy womenAntiepileptic drugsMass indexNoninferiority studyImplant useMass spectrometry assayPercent changeConcordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients
Wilson C, Lazorwitz A, Hyer J, Guiahi M. Concordance of Desired and Administered Postpartum Contraceptives among Emergency and Full Scope Medicaid Patients. Women's Health Issues 2022, 32: 343-351. PMID: 35272884, DOI: 10.1016/j.whi.2022.01.008.Peer-Reviewed Original ResearchConceptsEmergency MedicaidWeeks postpartumPostpartum contraceptivesMethod of contraceptionHospital dischargeOutpatient clinicPostpartum contraceptionContraceptive preferencesMedicaid recipientsHistorical cohort studyPostpartum tubal ligationImmediate postpartum contraceptionSafety-net hospitalRate of concordanceElectronic health recordsHospital stayMost patientsPostpartum coursePostpartum dischargeCohort studyMean ageInsurance statusTubal ligationMedicaid patientsReversible contraceptionDiscontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences
Novick AM, Johnson RL, Lazorwitz A, Belyavskaya A, Berkowitz L, Norton A, Sammel MD, Epperson CN. Discontinuation of hormonal contraception due to changes in mood and decreases in sexual desire: the role of adverse childhood experiences. The European Journal Of Contraception & Reproductive Health Care 2022, 27: 212-220. PMID: 35133231, PMCID: PMC9133050, DOI: 10.1080/13625187.2022.2030702.Peer-Reviewed Original Research
2021
Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period
Lazorwitz A, Sheeder J, Teal S. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period. Contraception 2021, 108: 65-68. PMID: 34973207, PMCID: PMC9011406, DOI: 10.1016/j.contraception.2021.12.008.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsImplant usersEtonogestrel implant usersSingle-time measurementsEtonogestrel implantsPharmacokinetic outcomesRepeated measures testSmall studyPharmacokinetic measurementsTime pointsPharmacokinetic studyConfidence intervalsMeasures studyImplant studiesMeasures testEtonogestrel